This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Entyvio
  • /
  • The Impact of Anti-TNF Exposure on Vedolizumab Eff...
Clinical trial

The Impact of Anti-TNF Exposure on Vedolizumab Effectiveness

Read time: 3 mins
Last updated:1st Jun 2015
Identifier: NCT02423512

Vedolizumab is a new medication being used for the treatment of Crohn's disease and Ulcerative colitis. It works by blocking specific white blood cells (alpha 4-beta7 lymphocytes) from migrating to areas of inflammation in the gastrointestinal tract. Previous studies have shown that patients who have previous exposure to another type of medication for Crohn's disease and Ulcerative colitis (anti-TNF medications) do not respond to vedolizumab as well as those who have never been exposed. This study will investigate biologic markers in the blood and tissue the help identify possible reasons for this difference.


Study Type: Observational
Actual Enrollment: 50 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: The Impact of Anti-TNF Exposure on Vedolizumab Effectiveness: A Biomarker Study.
Study Start Date: June 2015
Primary Completion Date: June 13, 2017
Study Completion Date: June 13, 2017

Groups and Cohorts:
- Anti-TNF Exposure
- anti-TNF Naive

Category Value
Date last updated at source 2017-09-13
Study type(s) Observational study
Expected enrolment 50
Study start date 2015-06-01
Estimated primary completion date 2017-06-13

View full details